Analyst consensus rating
Acrivon Therapeutics Analyst Rating: Strong Buy
Direct answer
Acrivon Therapeutics's consensus rating is Strong Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $11.50.
Forecast evidence checked October 27, 2026.
Get free Acrivon Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.74
- Average price target
- $11.50
- High price target
- $19.00
- Low price target
- $7.00
- Low target gap
- +302.3%
- Target upside
- +560.9%
- High target gap
- +992%
- Target range width
- 689.7%
- Consensus rating
- Strong Buy
- Analysts
- 6
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Acrivon Therapeutics?
Acrivon Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $11.50.
How far are Acrivon Therapeutics's low and high targets from the recorded price?
The low target implies +302.3%, while the high target implies +992%.
How many analysts are included in Acrivon Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is Acrivon Therapeutics's target upside or downside calculated?
The average target of $11.50 is divided by the recorded price of $1.74, then one is subtracted to produce +560.9%. This does not guarantee a future return.
When was Acrivon Therapeutics's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.